Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2461 to 2475 of 8213 results

  1. Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]

    Awaiting development Reference number: GID-TA11659 Expected publication date:  13 May 2027

    Technology appraisal guidance
    Awaiting development

  2. Ivacaftor–tezacaftor–elaxcaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in people 1 to under 2 years [TSID12295]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more responsive mutations in the CFTR gene in people 2 to 5 years [TSID12296]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Xeomin (botulinum neurotoxin type A) for treating lower or upper limb spasticity in people 2 to 17 years [TSID12297]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Filgotinib for treating axial spondyloarthritis ID6594

    In development Reference number: GID-TA11776 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Monofocal intraocular lenses for cataract surgery (provisional title)

    In development Reference number: GID-HTE10090 Expected publication date: TBC

    Health technology evaluations
    In development

  7. Subcutaneous olanzapine for treating schizophrenia [TSID12289]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Menotrophin prefilled pen for treating anovulation or during controlled ovarian hyperstimulation [TSID12290]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]

    Awaiting development Reference number: GID-TA11530 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Pembrolizumab before surgery (neoadjuvant) then with radiotherapy after surgery (adjuvant) for newly diagnosed, resectable, locally advanced, squamous cell head and neck cancer [ID6477]

    In development Reference number: GID-TA11599 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

    Awaiting development Reference number: GID-TA11130 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Filgotinib for treating axial spondyloarthritis ID6594: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 21 January 2026.

    Technology appraisal guidance
    In consultation

  13. Ex-situ machine perfusion devices for extracorporeal preservation of lungs for transplant

    In development Reference number: GID-HTE10084 Expected publication date: TBC

    Health technology evaluations
    In development

  14. Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]

    Awaiting development Reference number: GID-TA11765 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

    In development Reference number: GID-HST10062 Expected publication date: TBC

    Highly specialised technologies guidance
    In development